scholarly article | Q13442814 |
P356 | DOI | 10.1093/AJCP/AQW110 |
P698 | PubMed publication ID | 27543975 |
P2093 | author name string | Chen Lin | |
Jian Gao | |||
Yun Xu | |||
Lie Wang | |||
Ruohan Wang | |||
Qiaojia Huang | |||
Daiyong Wang | |||
Zaizhong Zhang | |||
Shaoquan Chen | |||
Xiaohuang Tu | |||
P2860 | cites work | Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis | Q37742318 |
Roles of VEGF-A signalling in development, regeneration, and tumours | Q38212662 | ||
Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer | Q41328969 | ||
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). | Q41643156 | ||
A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer | Q42224250 | ||
Clinical and prognostic significance of OPN and VEGF expression in patients with non-small-cell lung cancer. | Q51617107 | ||
Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. | Q54291995 | ||
HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. | Q54551877 | ||
Global cancer statistics | Q22241238 | ||
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis | Q29547178 | ||
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study | Q31081052 | ||
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction | Q33380002 | ||
Targeted inhibition of VEGF receptor 2: an update on ramucirumab | Q34040956 | ||
Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine? | Q35863874 | ||
Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro | Q37370761 | ||
Molecular basis of therapeutic approaches to gastric cancer | Q37386372 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | endothelium | Q111140 |
adenocarcinoma | Q356033 | ||
P304 | page(s) | 278-288 | |
P577 | publication date | 2016-09-01 | |
P1433 | published in | American Journal of Clinical Pathology | Q15750224 |
P1476 | title | High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma | |
P478 | volume | 146 |